Trial Information

Summary: A Phase II Multicenter Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma

You have been asked to participate in this research study because you have multiple myeloma (MM) that has relapsed (returned) after previously responding to treatment or that is refractory (no longer responding) to treatment.  The purpose of this study is to evaluate the safety and effectiveness of the investigational drug CNTO 328 in the treatment of multiple myeloma.  Your participation in this study is expected to last about 12 months and then there is a follow-up period that will last until the study ends.  The study will end 16 months after the last subject is entered into this study.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 2:44:52 PM